James Cullen Biography and Net Worth

Director of Avinger

James G. Cullen has served as a member of our board of directors since December 2014, as our Lead Independent Director since January 2015 and as our Non-Executive Chairman since December 2017. During the last five years, Mr. Cullen has held board and committee positions with various companies. Mr. Cullen is currently a director of Keysight Technologies, which was spun out of Agilent Technologies, where he was previously a director. Mr. Cullen previously served as a director and chairman of the audit committee of Johnson & Johnson and as a director and member of the investment and finance committees of Prudential Financial. From 1993 to 2000, Mr. Cullen was President, Vice Chairman and Chief Operating Officer of Bell Atlantic Corporation (now Verizon). From 1989 to 1993, he was President and Chief Executive Officer of Bell Atlantic-New Jersey. Mr. Cullen holds a B.A. in Economics from Rutgers University and an M.S. in Management Science from the Massachusetts Institute of Technology.

What is James Cullen's net worth?: The estimated net worth of James Cullen is at least $10,004.30 as of December 11th, 2023. Mr. Cullen owns 20,730 shares of Avinger stock worth more than $10,004 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Cullen may own. Learn More about James Cullen's net worth.
How do I contact James Cullen?: The corporate mailing address for Mr. Cullen and other Avinger executives is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. Avinger can also be reached via phone at (650) 241-7900 and via email at [email protected]. Learn More on James Cullen's contact information.
Has James Cullen been buying or selling shares of Avinger?: James Cullen has not been actively trading shares of Avinger during the last ninety days. Most recently, James Cullen sold 12 shares of the business's stock in a transaction on Tuesday, November 30th. The shares were sold at an average price of $8.55, for a transaction totalling $102.60. Learn More on James Cullen's trading history.

James Cullen Insider Trading History at Avinger

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
11/30/2021	Sell	12	$8.55	$102.60
11/24/2021	Sell	2	$9.30	$18.60
2/4/2015	Sell	153	$195.00	$29,835.00

James Cullen Buying and Selling Activity at Avinger

Avinger Company Overview

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.

Today's Range

Now: $0.48

$0.48

$0.63

50 Day Range

MA: $0.79

$0.47

$0.97

2 Week Range

Now: $0.48

$0.39

$5.45

Volume

539,643 shs

Average Volume

113,094 shs

Market Capitalization

$1.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.